<SEC-DOCUMENT>0001144204-15-035898.txt : 20150608
<SEC-HEADER>0001144204-15-035898.hdr.sgml : 20150608
<ACCEPTANCE-DATETIME>20150608060824
ACCESSION NUMBER:		0001144204-15-035898
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20150608
FILED AS OF DATE:		20150608
DATE AS OF CHANGE:		20150608

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36000
		FILM NUMBER:		15917310

	BUSINESS ADDRESS:	
		STREET 1:		XTL BIOPHARMACEUTICALS LTD
		STREET 2:		C/O ALSTON & BIRD LLP, 90 PARK AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		972 9 955 7080

	MAIL ADDRESS:	
		STREET 1:		85 MEDINAT HAYEHUDIM ST.
		STREET 2:		PITUACH, PO BOX 4033
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			46140
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v412639_6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of June, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: <B>000-51310</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>XTL Biopharmaceuticals Ltd.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name
into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; text-align: center;unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="width: 30%; text-align: center;unicode-bidi: embed"><B>5</B> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>HaCharoshet
    St.,</B></FONT></TD>
    <TD STYLE="width: 35%; text-align: center;unicode-bidi: embed">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center;unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: center;unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Raanana 4365603 </B></FONT></TD>
    <TD STYLE="text-align: center;unicode-bidi: embed">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center;unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center;unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Israel</B></FONT></TD>
    <TD STYLE="text-align: center;unicode-bidi: embed">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal
executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; text-align: center;unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: center;unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form 20-F</FONT></TD>
    <TD STYLE="width: 10%; text-align: center;unicode-bidi: embed"><FONT STYLE="font: 10pt Wingdings">x</FONT></TD>
    <TD STYLE="width: 10%; text-align: center;unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="width: 20%; text-align: center;unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form 40-F</FONT></TD>
    <TD STYLE="width: 5%; text-align: center;unicode-bidi: embed"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 20%; text-align: center;unicode-bidi: embed">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether by furnishing
the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to
Rule 12g3-2(b) under the Securities Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; text-align: center;unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center;unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yes</FONT></TD>
    <TD STYLE="width: 10%; text-align: center;unicode-bidi: embed"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 10%; text-align: center;unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center;unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif">No</FONT></TD>
    <TD STYLE="width: 10%; text-align: center;unicode-bidi: embed"><FONT STYLE="font: 10pt Wingdings">x</FONT></TD>
    <TD STYLE="width: 25%; text-align: center;unicode-bidi: embed">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If &ldquo;Yes&rdquo; is marked, indicate
below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-<U> N/A </U>&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: justify;unicode-bidi: embed">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; text-align: justify;unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: justify;unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: justify;unicode-bidi: embed">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Incorporation by Reference: This Form
6-K of XTL Biopharmaceuticals Ltd. dated June 8, 2015 is hereby incorporated by reference into the registration statements on Form
S-8 (File No. 333-148085, File No. 333-148754 and File No. 333-154795) filed by XTL Biopharmaceuticals Ltd. with the Securities
and Exchange Commission on December 14, 2007, January 18, 2008, and October 28, 2008, respectively.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tlogo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>XTL Biopharmaceuticals Provides First
Quarter 2015 Financial Update and Announces Focus of Efforts on its Lupus and Multiple Myeloma Assets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">RAANANA, Israel, June 1, 2015 /PRNewswire/
&mdash;&nbsp;<U>XTL Biopharmaceuticals Ltd.</U>&nbsp;(NASDAQ: XTLB, TASE: XTL) (&quot;XTL&quot; or the &quot;Company&quot;), a
clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products
for the treatment of unmet clinical needs, today announced that following an evaluation of the market opportunity for it pipeline
products, the Company has decided to focus its efforts and expenditures exclusively on its two core assets: hCDR1 for the treatment
of SLE/lupus and rHuEPO for &quot;no-option&quot; multiple myeloma patients. XTL also provided its financial and operational results
for the first quarter ended March 31, 2015.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><U>Focus on Core Assets</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Josh Levine, Chief Executive Officer of XTL,
commented, &quot;Following our analysis of the market opportunity and commercial prospects for our leading clinical assets, we
have decided to focus our resources and efforts exclusively behind the development of hCDR1 for the treatment of lupus and rHuEPO
for &quot;no-option&quot; multiple myeloma patients and to withdraw from further progress on a combination therapy for schizophrenia
in-licensed by the Company in 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Lupus is a debilitating autoimmune disease
and represents a large unmet medical need, with only one new treatment approved by the FDA in the past 50 years. A fourth quarter
announcement by Eli Lilly that it discontinued development of a Phase III asset in this space further emphasized the unmet need
and positions the Company to garner significant interest in our lupus asset from clinicians, lupus patients and partners which
will no doubt lead to &quot;game changing&quot; opportunities for us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">rHuEPO has demonstrated a significant survival
benefit for a number of end-stage multiple myeloma patients and results have been published in medical journals. XTL owns a use
patent and has obtained orphan drug designation for this application of the drug in the United States.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><U>First Quarter 2015 Financial Overview</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">XTL reported US$1.8 million in cash and cash
equivalents as of March 31, 2015. The additional funds&nbsp; from the US$4 million fundraise in April 2015, will allow the Company
to advance its hCDR1 program for the treatment of SLE and initiate a clinical trial on its rHuEPO for multiple myeloma asset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company reported research and development
expenses for the quarter ended March 31, 2015 of US$42,000 compared with US$47,000 in the first quarter of 2014. General and administrative
expenses for the quarter ended March 31, 2015 remain under tight control with US$0.3 million in the first quarter compared with
US$0.5 million for the same period in 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">XTL reported an operating loss for the quarter
ended March 31, 2015 of US$0.3 million compared to US$0.6 million for the same period last year.&nbsp;Finance expenses of US$0.2
million related to its investment in InterCure contributed to a net loss from continuing operations for the quarter ended March
31, 2015 of US$0.6 million, in line with results for the same period last year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Mr. Levine commented: &quot;Our first quarter
financial results are in line with our expectations and following the recent closing of a US$4 million registered direct offering
with a US based healthcare dedicated investor and existing shareholders, we are ready to execute our strategic plan with the goal
of bringing our programs to the clinic in the near future. We continue our discussions with the FDA regarding the regulatory pathway
for both drugs and have made progress on the chemistry, manufacturing and control (CMC) activities for hCDR1 including the production
of the drug substance. We look forward to the expected publication of the results of a Phase 2b trial on our lupus drug (PRELUDE
trial) which shows favorable safety and efficacy data on over 300 patients and are pleased with the coverage initiated recently
by a US research analyst confirming our belief that our assets provide significant upside as compared to our current valuation.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><U>About XTL Biopharmaceuticals Ltd. (&quot;XTL&quot;)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">XTL Biopharmaceuticals Ltd., a biopharmaceutical
company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of unmet clinical
needs. XTL is focused on late stage clinical development of drugs for the treatment of lupus and multiple myeloma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">XTL is a public company traded on the Nasdaq
Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTL). XTL shares are included in the following indices: Tel-Aviv
Biomed, Tel-Aviv MidCap, and Tel-Aviv Tech Index.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Cautionary Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Some of the statements included in this press
release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the
protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Please see the risk factors associated with an investment in our ADSs or ordinary shares which are included in our Annual Report
on Form 20-F as filed with the U.S. Securities and Exchange Commission on April 28, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Investor Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Arrowhead BID, New York</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Daniel Renaud or Thomas Renaud</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">+1 212 619 6889</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>enquire@arrowheadbid.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>www.xtlbio.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 100%; padding-right: 6pt; padding-left: 6pt; text-align: center;unicode-bidi: embed"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>XTL Biopharmaceuticals, Ltd. and Subsidiaries</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 6pt; padding-left: 6pt; text-align: center;unicode-bidi: embed"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>(in US$ thousands, except share and per share amounts)</I></B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 6pt; padding-left: 6pt; text-align: center; unicode-bidi: embed">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 6pt; padding-left: 6pt; text-align: center; unicode-bidi: embed"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Consolidated Statements of Financial Position - Selected Data</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>As of</B></FONT></TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>March 31,</B></FONT></TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2015</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2014</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif; text-align: left">Cash, Cash Equivalents and bank deposits</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,753</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,595</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Working Capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,033</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,485</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,013</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,743</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Long term liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total shareholders' equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,637</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,142</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Non-controlling interests</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">286</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>XTL Biopharmaceuticals, Ltd. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>(in US$ thousands, except share and
per share amounts)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statements of Comprehensive
Income</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>For the three months ended</B></FONT></TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>March 31,</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2015</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2014</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 6pt">Research and Development expenses</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">(42</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">(47</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 6pt">General and administrative expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(334</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(547</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Operating Loss</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(376</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(594</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 6pt">Finance income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 6pt">Finance expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(245</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 6pt">Finance income (expenses), net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(240</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Total loss from continuing operations</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(616</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(597</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Total loss from discontinued operations</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(460</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(164</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Total loss for the period</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,076</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(761</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Total loss for the period attributable to:</B></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 6pt">Equity holders of the Company</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,078</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(686</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 6pt">Non-controlling interests</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(75</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 6pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,076</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(761</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 6pt">Basic and diluted loss per share from continuing and discontinued operations (in U.S. dollars):</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 6pt">From continuing operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.003</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.003</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 6pt">From discontinued operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.002</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 6pt">Total basic and diluted loss per share (in U.S. dollars)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.005</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.003</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Weighted average number of issued ordinary shares</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">233,561,229</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">228,309,044</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify; unicode-bidi: embed; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: left; unicode-bidi: embed; font-size: 10pt"><B>X<FONT STYLE="font-family: Times New Roman, Times, Serif">TL
    BIOPHARMACEUTICALS LTD.</FONT></B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left; unicode-bidi: embed; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: June 8, 2015</FONT></TD>
    <TD STYLE="width: 5%; text-align: left; unicode-bidi: embed; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; text-align: left; unicode-bidi: embed; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Josh Levine</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right; unicode-bidi: embed; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; unicode-bidi: embed; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; unicode-bidi: embed; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Josh Levine</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right; unicode-bidi: embed; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; unicode-bidi: embed; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; unicode-bidi: embed; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tlogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlogo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`.`"C`P$1``(1`0,1`?_$`-$```$#!`,!````````
M```````)"@L!!@<(`@,%!`$``@$%`0$```````````````@'`00%!@D"`Q``
M``8!`P(#`@<)"@\``````0(#!`4&!P`1"!()(3$3%`I!47$B%1<Y88&AL3(C
M%C:WD5)SLW6V=QA8&?#10C-3)$2DQ"75EM97>!$``0$&`P0%!@@+!0D`````
M`0(`$0,$!08A,0=!41((87&!(A.1H;$4%3;PT3)"4F*R%L'A<H*2(S.#M#4W
M4W,D=1>B0S1$5%5E9AC_V@`,`P$``A$#$0`_`'_&AAK4NEP@L?4^TWJU.@CZ
MW3*Y.6NPON@5!90E>C'4O*.03#8R@H,6:A@*'B.VVO4.%&F)A,O+AZE$`=9+
M@WPBQTR\N9B9+DIS9C'<?>P>18YK<35#X]XB/Q]:SBR;&FV!S9PR7.5,KKH1
MDGEQ9R:</"V5\P#U"HDCEVJ"AP(;U``3BT<ERX2D6C^-.3Q36E)>$N'"\A_7
MYV@2)K)/IGR$2@]E!3MK\W9^=GJ'&_.]*Y/X+Q3R`QY[8%,RW28*[0*,@0J<
MBR;3#/K7BY`A!%,KZ*>$4;+"41(*B0B4=M+-59";HE9F:)/)=&E%.)V$@G'S
M/:<*=4)6JR,O/RA_5K#QT;QV-G?5FV28T,,:&&-##&AAC0PQH88T,,:&&-##
M&AAC0PQH88T,,:&&-##&AAD>N\Y1.9$CQ*FLL<'<V9(Q7F#!WM][F*K07+#;
M*E`:L^JUP2K!_&R8+V*`8(_2,:*0$45]!9#YPK$`-WTWF+9^\T.7NJ6"Z--$
M)*CFDG`'H>VGWG+U<494S0YA2(TH]1`V@!^S<-AP[69*\<^]WS4@LQ4[^M/R
M#R=G?C=8SR-(SIBVU+PZL?8L77J+=U6W.&8L(5D];SD+$RJCUD<BA?\`6$"D
M$!`PAIH;HTBMJ-03.VS+&3K*>]#>=HQ'E=YV@>D7_6DS_AUB8,Y23@H8[>O%
M^YE!W?NM.8K=?HVP8>Y1X3EN)]M]DMM1RC,$LAKTSQG,I(2\4X/6&<:I`S,N
MC!.2=+DLHV:K"7U%`2`QBAJL'F#EI*D>#4))7M]'=Z'C#/LW-L"M)9J/.>MR
M,TDT99XGE^`../4]M,N7W=LSYA_)<9QO[>G(?(.(^)/%ZG0N!L8*59Q"E6R:
M>C"NTM.6)YT^B'QWCRYV8[I9N*8D1*S!,2E`3#K9+5TMI%3I"KBOB6XJS45E
M8^J%8@=#@V*KEY5&FS*:=;$R11Y,.?EQ8X];R2R['%^U=R&F=FSF)SMY(<J,
MT2^5;MA";MG'"%L#J&0=8OI\0*2T3D)-DC!-_3M5W75%=MZY5"HQ141`FZYM
MH7N"3LR9U0D[:H,ND4<10F(?I')0?T/\Q:0Z7.W++V1.5FK3"C4^$E'U0\.P
MZ<F:]AWGNZD(`/\`7DSIX@'^U5S_`,8TRO\`I)I__P!L'E'QM#OW^O3_`*M?
MG;E_?.=U+^W+G$/E>UH!_<&M`.JC2.P#E2GCK_&U#J+>0+C-D%C^^<[J7]N3
M.0_([K8A^Z%9$-4.DFGXSI;CU_C8&HEY'$32B.UC^^<[J7]N3.8?*[K8?A&L
M[:/])-/S@*6']?XV#J)>0SFE>=E5.RCW-.?G(3N4\>L2YKY5Y5R3C2TIY+-8
M*;9'<&I#RXQ&,K7,1@.RLH1FX$6DHR16)TJ%^>F&^X;AJ-=4M/;.MRQ)BKT:
M5=6`H=F(&#;;8=XW)5[HEY.?FBJ#B\;#@2YV3\&D"@\@^0/Q:4IF0:NAAFWV
M+N4G(:8[NT_A"1RY<W>(VV7,F0[>A.7#$]<2B(FKS+N,CTTBL2.P18N&R9R?
MGMP,7QWTZ%>TLL2!RRP[Z12EIN-5-@*5.<:N$J5-!!/"_A>4X9=+<Y;9U<U%
MGN;V-846J*-FIJ<PD29=@E,JH@`N>X$`N>YX.#.0=)>W1IJ#Y#Y^0^7GY?!]
MW0,V-N&;:%=PQYGMAQ8M3KC2-T+F$MAII(8<?-@>6GZ,4L3,L[[$W,@Y$Z/T
M6*GKCT"($ZA\-2/I;`LR9U"EH-_$"URA?B/+@[A+GEX<.)W8YH-UYBW_``-*
MIZ)IMXOWT$6#P^J8K=X_>X0?JO?VM;O;1?\`)"1X[KN.5!K\;*(9"LZ1?K(9
MBQL/Z,I(Q/T/Z3?V=L/T=ZIE_3-T?.'?Q'62UYDM/Y"^O#TV4@VW[/A%)EE<
M:>,_+>23WGNPV!L1RSS6HL[IQXFJ/M'[RBHQ`?7$N7PAW"[`%V;MC\L&48U$
MS,2QH88T,,:&&ZU$R*E$BA2G(8IBG(<H&*<A@V,0P#N`E,7P$!\!`=##1L/?
M[[;!N$/*1QE3&L"=GQPY'R<Q:Z:1@@/T90LA&.,C>,;B!2@DS9F67&4B4QV#
MV)=1(FX-3;.[HM?PN>WS1ZB7UNG@$/\`G)R!Z=QZ<=K*SJ5:IH=3]HR6%)G"
M>Q6T?%Y&ZL5=[?*>-.TQ>N!K%Q.ERL><^KG&V4"*&!2K\<K6V=/+?#%D`6!T
ME8HA7U(B+$"CT1LEU`8HM2;VM2TEDZCJ,BY5?R3`Q!A_QPQ`<[(EQ/XV^DCJ
M'-25H*MX`^U7N2K<DGX99=+8Q[(W;6?]P7E+'.+I$NQXU81<1-QS1)'242C[
M$J1P*]5Q6V=[>D9[;W345'I"&$R44BL(](J)B.5UCOT6C0S(R9=7)X.'0!@]
MVQVQK+3VV%W%6'SCS293O*Z222[I>7M)L&K4"I"!658:(5K96"$42OJ1C)2$
M)%M44V[:-"+41,Q%@W;HD(1$4^@I2@````&D8XE<7&\\;\]K-;PIX>%PX79-
M:'U-8A_]6XX_[%JO_2=?4SD\[Y:_TE?&WP]6E/H0_P!%/Q-'+^\BP4+7.Z=D
M.*KL-$P,6EA_"JJ4;"QK.*8)K+UQVHLJ1HP1;MRJ+''<Q@+U&'S$=.MH-$B1
M+#EUK42KQEYGZY98=6DI3=KD@`<"<NH,Y2]V3Q[0K1VRV\I9:13[!)#R#S"W
M-(3=8@I9Z#=!2O`B@#J08N''HI;CTE$P@7<=M01KG.3HU`B)"U!/AIP!('SM
MQ:6-*Y>5-I)44I)*R]X!V!LQ^\,XUQU7NU+R!E8"A4N#E&T_B`&TE#U2!C)!
M#U<JU))4J#QC'MW*0*IG$I^DP=1!$!\!'5IHS-SBM1I(%:RDOP*B7X'>2UUJ
M/+2J;1FE)2D$$8A(&W>`S0OW>S[7#BY_!9<_9#==,KK;_3N8[/XMH,TT][I7
MX;%-)Y!Y!\@?BTB#-PU=447))&;F&:$P61Z9B#O'93R3?I=O7J=3\LYAFIR4
M<[F!LV1J,^BFW;HE`RCEX]<+$112(`G45.4H!N.NED>E5BY.46FT*ARAB5B>
MI].P&U\WGV'/8`\EN0U-K]#L[G+J=T5Z9$G19*I5(DG:Z7(X?SGNZ\&V9M?>
M;Y,WV9DGO'#C`$CC^-=*-TYFPUN\W*5?-TC"`JOCU48Z'AU%2EZO1(HL9,!V
M,81`=1;3>5ZPZ-*<&HUT0:?7E`.A)X>T8DE6Y[AU-*]3YR]3+@G)A6FUH*G:
M&E6"RF:FGNVOEG(3Y7!L^\3>]!7LF7F.Q=R+H+'$,_,R)(6*MT2]D%Z@$ZH<
M$&T196$XD26JKETXV3(HH=9$JA@*<2`/5K3M1N5:O6I1C=-ES0JMNAZNZ'K"
M1CD">(@/)<XN&1:0=*^="BW373:VH<G[!KW$$![^`J.`!X@"G$@8[V4HYI<C
MG?%3C_:<VQ=8:75U6GM;9)P#J34AVSLMAFF<09<TB@U>*H^SE==8`4@@80V\
M-]]0=IE8YU*OF4LE,V))<XE1XB'\/"DJQQ&YV;,?K!J*G2K3^8OH2GKQE5H3
MP@N?QJ"7OW//G:V>"_*>0Y?8+1S!+T]G27*]NL593@HZ66FD?3@O80*[!\X:
M,U3*N?;?$@DV*)?,=7NK>FJ]+;UCVH9L3RH<G#45`<(/%BYSSY7XMB-#=68^
ML=C&[IF4]1\2HQ)4(>_]FXO?VMJ5S5[N6-^.%JD\68PK(Y@RK%N"1\ZF20&/
MIM4DCFZ!B).29)NI&7G4]P`[-H3\T8P$.H4_S-21I5RVW-J+3OO-49I-,MP#
M!<3-3L20G`!+G]\D!^+B,6BO6GFTMC36JJM:W)0U.\!@I*?DI)P<2D$DO=@,
M6TA<]W7GO56@72Z<28>.QTKT*$DG],RI6V!&9Q`Q3!97SETS)NC^2HHB!1'Q
M$/@U+D7EHTBJD+V+1+N@BXMYFI127[<`05=04]H(C<W>OM-ABMU:T%>P27.]
M3G$=W>)DO!P^JYE:^%'<+Q!S-BW[.`0>TG)4"V*[G\=6!RW7>BPW(09JNR*`
M$0L,(54P$.J4B2J)Q`%4R[@(K?JIHM=NDLTGVLCQZ(M7##G4CNKW/P[JCN\C
MV;31/F!L_6>5,.EK]5NF&E\624<4@9D'YP'1DR@VHG9@&-##)+=[FO<;;!VW
M.0Q>3KTL34(JO$EZ),,DVJUIC\S-#&#&(4QNY42*\GY"?4*U.AU`55@LY!02
MI=9@W/3B9K4K>\B:('Q?$#]W"_O/SP=CUN;3[]%,^ZDV:J[PN'#?Q;'?#)HM
M`O6)0ZM@4$`ZMMQ*!]O'[H@!M=%0]SSG^%DY+GESW>=S26GNZ,_QJENVQCR-
MP"S+&V:`G)AER'822K9:UGS<N9->:EYI1$B1EHB8B!:*0IND$RQA4T@^>DKI
M!]9$UL7].&M%X+N#=P.P=^%VWL9M]-_9OW2EA)AQ!/%OXGG/\#+R:B]M_8U0
MY,-&P>\O_:NY'_H<P?\`S:=:=K03W`@?WR_MJ96M6_>[]VG[(9S7[KS]EZU_
M^B,S_P`;6]0)KU[^)_RU'I:7-)O=!/Y9]`;-?O&7V2O(;^7L-_M9I^K+1?\`
MJ-(]OH4UYJ9[GS76GTAF:ON]?VM_%S^!RY^R&ZZ9[6W^G<QV?Q;0)IK[W2OP
MV*:3R#R#Y`_%I$&;AJZH<0YAF3N7<3$SGW5\@XD7.JDQO?**1@I95$PE52A!
M?%?3JB9@_(4"(9+](^91V$-AUU7M2Z%V?RM2ESP_VTE1N%+_`*2B4I_VB&XF
MWA9R+\YN)VSHO["=K:BK\D=]0[4@AGE=-I=7QY6HBH4N$CZQ5J^Q1CX:#BFR
M3)@P9-D@232322_+,(?..H8144/N8PB81'7+*?GIRL3QJ-4CJB56(7K45%3R
M2\Y^0#(;&[-T:D4RA4V7H]%ED2=(E$A*$)``<,!@/.]F]_?,X\TYA7*!R1K,
M,VBK,ZM`4"]/(]`C4D^SD8M[)UV3DP2*3U96.=12J!%Q_.&16`#&'H*`.IR=
M7K5O;$[IS5)LF@)AJG`DXN)[B@!M#E8C+![<\.>K3RC0Z?3-2J5*)15(M1]4
MG5##B/"HPR>EZ2']3>QFC*TIF+L@Q5OL#M:0L"#?']1GI!<QE%W[^F9)9UTC
MQ50PB*BSIC&I*',/B)S"(^>L;8=L2-G<X"J3(_R.$9@H&T<4MQ`=3U8=`;*7
MU=D_?/(Y#N"=_FT3P)>(7YF4G/#?UD0\>DMV\&,P/<"=G_+65(H_ISE7L>5/
MT<4V`PI6.=<P,%!+])AZ3"VDY)-78?#<GCX;Z]Z\6Q"NWFLI]M1QQ2TW*T]:
MQO2A2E+&&]*2.IO&@5XQ+&Y0*Q=<)XF):=GT(.Y<1,!"#V*4#V-B?LD\98+(
MEGR)R>R)'$M,C4+"C6Z.:;*5^4+=(M2SEGN"Q7/J>U3+=L_12054`PIG<*G#
MYX%$-HYO]0*C0Y2DZ;6]_@9>8@^)&2@N?)C"##PV'A+^H!M7Y(M-Y*XJM5-4
MK@2)Z-+11#@E>)$V>]%7CFX$./2]G.T@Q9R3)VPD6C5^P>-UFSQB];I.F;QL
MNF9-9NZ;+E.BX;K)F$IB'*)3%$0$-(4DJ2H+AGAB`O!W$9'#<6Z=1$I7#4E8
M"D$%X.WH[6:`<NZ2';M[AU2OV)05@:D\=5G)]?A6BAB,V%?FI5W"WNF`F4P`
MI!N!9NR)(B(@1%4A?\@NND^F->&O&@T[;5V.GJA#1$ETK(Q2J7A^)#B8_.!"
M2_:06Y"ZNT?_`.<^9.G5RR>*3I4T84T4#$"!&7PS4,CZ)5Q@#8'.9V5]8-<W
MV]8WZG?IWY%_5SIW]K_+_*_!]W7-_P!FS_TO]YX?YV[K;JY]Y:5P<>/\O]>_
M=\7"_K:_S&*4-Q$```$PB(@```>(B(CY``:MVV%HX?W@KN<_USN11L!XHG?:
MN-_'2=E(E@ZC77_+<EY60,>,M-X4%$0(\B(`"JQ<.81,44RN'!?!P&SF:'V!
M["I?W@J`X:S/8)!S2G9AL)S/8-C+!J;=1K=3]G23S2I/-V2CD3CGN\[8HQYV
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M&2<-'C18BB:A1$IR&`0$0\=(J04DI5@H9LV"5)6D+07H4'@[P6]/7DY-Z:-@
M]Y?^U=R/_0Y@_P#FTZT[6@GN#`_OE_:4RM:M^]W[M/V0SFOW7G[+UK_]$9G_
M`(VMZ@37KW\3_EJ/2TN:3>Z"?RSZ`V:_>,OLE>0W\O8;_:S3]66B_P#4:1[?
M06O-3/<^:ZT^D,S6]WJ`1[N'%P``1_,Y='P^(,0W41'Y`#3/:V_T[F.S^+:!
M--?>Z5^&Q32>(>0?(&D09N&KH89HM1I2/A>]]).Y55)!JMR=O,8DJL8A"$D)
M2OS,='`)CB`%,L\<$(7]\8X`'B.NCM5EIR:Y/(1E`7"FPB1T)C`GR`/+<B*!
M,2TGSU1E3F`]KQ4@G``J00D]NQG<X&*8-P'P'?\`!YZYQ9MUV)`S9$'OM66+
M8<5:-5UU@+*VG,,,_CD0,'4HVK5>L"\FL)?]$D201`3>0&.'QZ:ODWI<S,ZJ
M3-8'R)*BS+\,^):`/0R0\]U1EI;224IF'B3U9@$;^[#620,SL;4V8K3^K=A9
MB201,W4L<_&6QFF?J$_T;/9D*ZCEC`(!T^TM4RJ%#]Z8-2-)5&5J'.O$5).*
M$^(,,GB4`(ZP<VBJ?IDS2.0B#!FL%3<2$KL7.<0^RWC8:K;^T]C+-S.,(JJZ
MC+U:+,H@B'4=9C6[13)62Z@#Q%)%@@HH;[A-7%]U26HW.52YN<^2J'`2_<52
M\8)\Y`;'V%2IRL<C%8DY+%8J4PKI(3,0"?-GY6VD[#MUB7F!<M4--=,M@K64
M$+"[;"<OJ&A[56HIM'O2E#Q,E[9!N$A$-P`Q0`?,-1_SE4Z;@Z@255B`E,6D
MP@"[!Z5*>-S\1AFTG<@]9E(VF]3H$,@52!5HBECZJDH<K>[ND/R>R\QAV*/R
M#^+2CC-GU4"4EV;F:6][F:;7/EUC*B0(D?3=?QO7("0;(@)EB3ESMDF^B(X_
M0!A.NHT<MU`+YE!;<=M]=$.4&1F:3IE4JY%(3!7/QRDG!Z4P>\1O&8P;DMSS
M3,"M:RTB@4W&JIIT%"W;/$BEP.[`[79LY`_0"8WZNDFWU!?5SOX?K!T>EMY_
MYOK\-(E[?ICG_P#F_%_,>[R-T>^YM0X^#_UCV=^=P\;V2-[^W.;*?&_C6.!^
M.E.R%8<[\AXN4A%;%0J?:+!]6.+-@C[98SR4)&/48ZRV$JPQD60Q@5)ZB[D`
M`42".XZ1VM3Z_<XJ5<*!1)$\:@H@<1V!QSR>>QKN_P"N3E+H_JTBE1JTYW0X
M$N&1R\GE9F%VU^V-F+F=RXQIA^YXRR90L7-WH7',%OLU,LU:91V.JVNW7EXM
MA)3,:R05G[4JHE&M"$,90#N15VZ4S"#/:CWW3;9M=4Q3EH563@AQ!SRR)R#0
M19MHS]:K*9:=2M--!)42"/3@]I16"I59K-2B:'!PT;'4Z"@&55AZT@S1"'85
MF.CTXEE!I,A**`QZ$8B"'IB`@9/P'?<=(4N+,18QFU']825=I+V;%$M#ARHE
M$?L@EW8YSO(T:5WA^UKD3A[S%N</AW%M]MV!LL&=9,Q&\I]/L5H9UJ-EGRH6
M#'TDK"Q[\K%S3YHYTFJ:O092.5;G#?YVSQZ37](W);O'5%I%:AN22HA+W#`X
MG:&5J^;.FJ+7BNGH4:6HO#@2Y^8RZV<C>[=\T<PV7$[_`(1<BZ/DR`LV&X92
M9PA<+O2;7"-+%BPBY4WE%7F)B*:M33%!>.@%DFHH"BT4L!"`(-1U".MEL4N2
MJXNF@J0:5/'$`@D*VD@'!Y\_6TJ:8UJ>F)-5%GDJ3ZF'@D'([,O)T,Z<^#4&
M;&EAHZ+WCS$>6+CW2LB3=1Q7DJV0JV(<*((S-9H=KGXE5=O6G97#=.1B8EXR
M46;&$`4*!^H@CL(!IS-!ZG39"QE)GUH"_%5@5`'Y1WE[++JO(SL:ZA$A)44<
M"7$`G8&<D^[,56U4WMGMX2XUBQU&9)R!S`Z&(M,%*5Z4!JY/7C-W7T?+M6;O
MV9?I'H/T=)MAV'PU!>M\XB>OZ)'A*2I!AIQ!!&'%NZVE72Z$N#:J840%*PLX
M'L;,?O"E>L5K[56?X.J5Z<M,X\GL0F:0M<B)"<EG14,J5-=<S>-BVSIZN1!!
M,QSB4@]!"B8?`-6FCD[)R6HDE&G2!"'$]^&8+L6NM1X:XEHS*$`E1*<NMHZ"
MH8NY6X^GF%KH>,N2%(M<7[0$9:*A1,HUNP1X.VZK-T#&9AHEE(M`<M5SIJ>F
MH7K3,)1W`1#3M56I6E6I,R%15!5#.8*DD';B'XLKDI+5R3FO6Y1$0+Z`7^AL
MX?65W0?AN_/K[TYR.#_B-:_[*TS_`+"C>1#9KUF[_P"UJOE5\;4^LKN@!X_I
MMS\';X/IWD=X_P"\:H:5IHX_J:-EN0QZQ=ZN[XM4QPS5\;*_\.>/G*;.JV.6
MK*%R<TS&M5I*^L[;D.-MD=,RMNJK!:QI$D;59&@*IV6268`FV6>+&ZW`D*<V
MPZEV<OVP+)TLD92K&%&HJPF$J&A2%%*5DI)*`7A("B3ADR(533/4>]]<ZA#M
ME$6'5(:C&0I25@$R03PCC(`))`=CBRY<!WL<M8@B4Z%R.XS3#K)T"4(>2E`F
M5J,M)NV8>SG>RE>E8%\+9ZY,3=0[-4[=4=S)@!1`-+;4.5.VJ_/(J]A7)+>P
M)T\3HA`*$];R]W2$X,Q]-YU;PM635;VH=LQE7C)=Q12E0"SEM!<3O!<6UK+5
M>6G=\SU7[%::L]QW@^KK%:(OP8R3*F4ZIN'B3B71A'DLBW6N5VL*2!2=:0"4
M#%()O212Z=2.BJ::<J]CS-,HLT*I?<^25*!!(.+E*<HCU7'NI>]^+FC$4G5C
MG#U"@S=2EE4VQY#`X*2F52"\PH?$`532L`I0P=N`987N=XZ;UOMU6O&>.ZW(
M+1];3Q57JW7(*.>2;PD1`6>";(HMVC)%PZ<&;M&O6H?I'<=S&'Q$=+#R[UQ2
M]?I&N7!.`*G(T]$4M1<'K@*.)+@,<G[\&<;FBH"9+EQG[=H$H5)DX=/0A"4E
M1<F8A#``//"`27-:?:`HZB_!9[2[[5Y)JTFK_E&/FJ]9X=Y&JO828)%LW2+A
MA)-VZXMI!JH<@&$NP@`B`_#K,<TE8AKUS55J7-)6E%.EUI4DA20M&(+P\=TC
M)L%R>4*(-`U4>X)-8\6=J"%(4"E12M$%)<#CW@2`>ADNK[@/E-VI>04EF/!]
M?EK]A&24=MB/DV$A.P+^FOUQ>%I>1V<,)Y*&D894H`WD`*"0G(55,_4=1/3`
M4F\]+^96Q(=I7G-^R[X00227%*Q_S,J2Y/#$R6A[W'J++%7K!U6Y4]2XE[V#
M*JJ5C1'@.!*5(4__``LV$][BAC%*\G@$',-GJ<[\]HF:\K$T#C,JSR&Z0!HV
M<2UM=V"$9R*B?1ZZ%?B*\SF'XI*CNF@=9,3;`!A^/1*9R>2D&LJB5JY)95!2
M7N0I/'$2,TN4>%)4,`7J#RT@S_/A5H])$*CVT4UM8(>J-$4A"B'!3@AZ@#B1
MM<W#M\<"\V9CSHGS-Y>L9IGT67].*]7[>U!G8KO<E"@K$S\C"*`4T%5:\()&
M9H'3(=8Z*1"IE13$37NMFL%DVK9"-']+"E92D(BQTXIED?.@P5#`S"@],58P
M<58O.'C0#06\[XOQ6M6KTN4H6KQ(4%?RIF)FF-%21A`!<J&DXD@8.&+E[I#X
MO@V_#O\`CTC3@W2AY;EJK#&AAC0PQMMY:&&-##&AAC0PU-O'?_#PT,-70PQH
M88T,,:&&H(;@(?'\?C^#0PUL2U6K<X9):9@(6661`"IJRD1'OU4B@.Y024=H
M*"F`&\0`/AU](,>;AX0(RN'K(]#6,[3:=.N]>EX<R1])*2[R[F]YJU;M4B(-
MTTTD4BE(FDD0B2:9"AL!4TTRD33*`>0``!KR26N(,*#"#H(<&^D0W$!\/#[G
MWOO:\M]F`#;_`!CH8;@HF14IBJ%*<AB'(<AR@8IR'#8Q3%-\TQ3!Y@.X#HQV
M9M0N((5\DC'J:T6M2JK)W[<PK%>8O!.!Q?,X.+;/.L1\3^TH-"*]0_".^^KA
I4Q-JA>$J.HJZR1Y'MC)>ETJ6C>/*R\DA^U,,`^4#-KRU;ME&-##?_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
